Yesterday, the Intl. President of Intercept Pharma (ICPT), Lisa Bright, sold shares of ICPT for $557.1K.
Following Lisa Bright’s last ICPT Sell transaction on October 04, 2017, the stock climbed by 38.1%. In addition to Lisa Bright, 2 other ICPT executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Intercept Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $46.99 million and GAAP net loss of $64.45 million. In comparison, last year the company earned revenue of $41.33 million and had a GAAP net loss of $72.6 million. The Company has a Price to Book ratio of 33.0594. Currently, Intercept Pharma has an average volume of 368K.
Based on 11 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $145.81, reflecting a 36.5% upside.
The insider sentiment on Intercept Pharma has been negative according to 46 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
